Organization
Hopital Foch
1 clinical trial
4 abstracts
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Clinical trial
Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind StudyStatus: Recruiting, Estimated PCD: 2025-03-11
Abstract
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.Org: Nantes University Hospital, Institut de Cancérologie de l'Ouest, Angers, France, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,
Abstract
Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019).Org: Centre Léon Bérard, CHI Créteil, Rouen University Hospital, Hopital Foch, Nord University Hospital,
Abstract
Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer.Org: Institut de Cancérologie de l'Ouest, Angers, France, Nantes University Hospital, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,